Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Shire

ClinicalTrials.gov Identifier:

NCT01989169

First received: November 14, 2013

Last updated: December 16, 2014

Last verified: December 2014

History of Changes

Results First Received: December 16, 2014

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Open Label
Condition:	Healthy
Interventions:	Drug: Midazolam Drug: SSP-004184SS

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Midazolam First	Subjects received Midazolam 6mg in Period 1, followed by Midazolam 6mg and SSP-004184SS 30mg/kg during Period 2.
Midazolam + SSP-004184SS First	Subjects received Midazolam 6mg and SSP-004184SS 30mg/kg in Period 1, followed by Midazolam 6mg during Period 2.

Participant Flow for 2 periods

Period 1: Period 1

	Midazolam First	Midazolam + SSP-004184SS First
STARTED	15	15
COMPLETED	15	15
NOT COMPLETED	0	0

Period 2: Period 2

	Midazolam First	Midazolam + SSP-004184SS First
STARTED	15	15
COMPLETED	15	14
NOT COMPLETED	0	1
Adverse Event	0	1

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Midazolam First	Subjects received Midazolam 6mg in Period 1, followed by Midazolam 6mg and SSP-004184SS 30mg/kg during Period 2.
Midazolam + SSP-004184SS First	Subjects received Midazolam 6mg and SSP-004184SS 30mg/kg in Period 1, followed by Midazolam 6mg during Period 2.
Total	Total of all reporting groups

Baseline Measures

	Midazolam First	Midazolam + SSP-004184SS First	Total
Overall Participants Analyzed [Units: Participants]	15	15	30

Age [Units: Years] Mean (Standard Deviation)	37 (10.45)	44.9 (10.53)	41 (11.07)

Age, Customized [Units: Participants]
<=18 years	1	0	1
Between 18 and 65 years	14	15	29

Gender [Units: Participants]
Female	4	5	9
Male	11	10	21

Region of Enrollment [Units: Participants]
UNITED STATES	15	15	30

Outcome Measures

Show All Outcome Measures

1. Primary:

Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Midazolam [ Time Frame: Over 72 hours post-dose ]

Show Outcome Measure 1

2. Primary:

Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measureable Concentration (AUClast) of Midazolam [ Time Frame: Over 72 hours post-dose ]

Show Outcome Measure 2

3. Primary:

Maximum Plasma Concentration (Cmax) of Midazolam [ Time Frame: Over 72 hours post-dose ]

Show Outcome Measure 3

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.

Results Point of Contact:

Name/Title: Study Physician
Organization: Shire Development LLC
phone: +1 866 842 5335

Responsible Party:	Shire
ClinicalTrials.gov Identifier:	NCT01989169 History of Changes
Other Study ID Numbers:	SPD602-117
Study First Received:	November 14, 2013
Results First Received:	December 16, 2014
Last Updated:	December 16, 2014

To Top